Intech Investment Management LLC Boosts Holdings in DexCom, Inc. $DXCM

Intech Investment Management LLC grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 156.6% during the 4th quarter, HoldingsChannel reports. The fund owned 212,220 shares of the medical device company’s stock after acquiring an additional 129,504 shares during the quarter. Intech Investment Management LLC’s holdings in DexCom were worth $14,085,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. CVA Family Office LLC raised its stake in shares of DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after acquiring an additional 147 shares in the last quarter. ORG Partners LLC raised its stake in shares of DexCom by 124.3% during the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after acquiring an additional 281 shares in the last quarter. Spire Wealth Management raised its stake in shares of DexCom by 113.8% during the fourth quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock worth $38,000 after acquiring an additional 305 shares in the last quarter. Aventura Private Wealth LLC purchased a new position in shares of DexCom during the fourth quarter worth approximately $43,000. Finally, Rothschild Investment LLC raised its stake in shares of DexCom by 59.9% during the third quarter. Rothschild Investment LLC now owns 654 shares of the medical device company’s stock worth $44,000 after acquiring an additional 245 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on DXCM. Bank of America decreased their price target on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. William Blair raised shares of DexCom to a “strong-buy” rating in a research note on Friday, May 15th. TD Cowen decreased their price target on shares of DexCom from $84.00 to $75.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Barclays reissued an “underweight” rating and set a $64.00 price target (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Finally, Raymond James Financial set a $81.00 price target on shares of DexCom in a research note on Friday, May 1st. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $82.42.

Insider Transactions at DexCom

In other news, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total value of $107,168.00. Following the transaction, the executive vice president owned 111,204 shares in the company, valued at approximately $7,010,300.16. This trade represents a 1.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the completion of the transaction, the insider owned 382,482 shares in the company, valued at $27,538,704. This represents a 6.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 32,871 shares of company stock worth $2,306,638. Insiders own 0.28% of the company’s stock.

DexCom Stock Up 1.9%

Shares of DexCom stock opened at $73.74 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98. The stock has a market capitalization of $28.45 billion, a price-to-earnings ratio of 31.51, a P/E/G ratio of 1.20 and a beta of 1.40. The company’s 50 day moving average price is $64.17 and its 200-day moving average price is $66.44.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter last year, the business earned $0.32 earnings per share. The business’s revenue was up 15.0% on a year-over-year basis. Equities research analysts forecast that DexCom, Inc. will post 2.57 EPS for the current year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.